A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature review

Figures & data

Figure 1 Chest computed tomographic scan before treatment (A) and after 3 months’ treatment (B).

Figure 2 Paronychia in left ring finger (A), papulopustular rash in right leg (B), the thicker eyebrows (C), the darker beard (D) were found, respectively.